摘要
目的探讨消渴丸联合甘精胰岛素对新诊2型糖尿病患者[糖化血红蛋白（Hb A1c）〉9.0%]的临床疗效。方法选取本院内分泌科2015年3~9月收治的60例初诊2型糖尿病患者作为研究对象,随机分为治疗组（A组）与对照组（B组）,各30例。两组在控制饮食与运动的基础上,于三餐前30 min,A组给予口服消渴丸,B组给予格列苯脲,两组每晚均于固定时间注射甘精胰岛素,治疗12周。比较两组治疗前后的空腹血糖（FPG）、餐后2 h血糖（2 h PG）、Hb A1c、BMI及低血糖发生情况。结果两组治疗后的FPG、2 h PG、Hb A1c水平显著低于治疗前,差异有统计学意义（P〈0.05）。A组治疗后的FPG、2 h PG、Hb A1c水平显著低于B组治疗后,差异有统计学意义（P〈0.05）。两组治疗前后的BMI指数比较,差异无统计学意义（P〉0.05）,且两组均无低血糖发生。结论消渴丸联合甘精胰岛素能有效降低新诊2型糖尿病患者的血糖,且对患者体重影响小,具有安全、方便、依从性高的特点,可作为临床2型糖尿病的治疗方案。
Objective To explore the clinical effect of Xiaoke pill combining with insulin glargine in newly-diagnosed type 2 diabetic patients whose glycosylated hemoglobin was more than 9.0%.Methods 60 newly-diagnosed type 2 diabetes mellitus patients in our department of endocrinology from March to September in 2015 were selected and randomly divided into the treatment group（group A） and the control group（group B）,30 cases in each group.On the basis of the dietary control and exercise in the two groups,oral administration of Xiaoke pill in group A and glibenclamide in group B at 30 minutes before three meals was provided respectively.Injection of insulin glargine in fixed time at night was implemented in the two groups.The course of treatment was lasted for 12 weeks.The fasting blood-glucose（FPG）and 2-hour postprandial glucose（2 h PG）,glycosylated hemoglobin（Hb A1c）,body mass index（BMI）,and occurrence condation of hypoglycemia before and after treatment in the two groups was compared.Results The level of FPG,2 h PG,and Hb A1 c after treatment in the two groups was lower than that before treatment,with significant difference（P〈0.05）.The level of FPG,2 h PG,and Hb A1 c after treatment in the group A was lower than that in the group B after treatment,with significant difference（P 〈0.05）.There was no significant difference in BMI before and after therapy in the two groups（P〉0.05）,and there was no hypoglycemia occurred in the two groups.Conclusion Xiaoke pill combining with insulin glargine can effectively reduce the blood glucose in newly-diagnosed type 2 diabetes mellitus patients with little influence on body weight at advantages of safety,convenience,and high compliance,it is worthy of clinical promotion and application.
出处
《中国当代医药》
2016年第23期111-113,共3页
China Modern Medicine
基金
江西省赣州市指导性科技计划(GZ2015ZSF091)
关键词
消渴丸
甘精胰岛素
新诊2型糖尿病
Xiaoke pill
Insulin glargine
Newly-diagnosed type 2 diabetes mellitus
